Related Experiment Videos
Phase II evaluation of PALA in patients with refractory metastatic sarcomas
Abstract:
The efficacy of PALA was evaluated in 22 patients with metastatic soft tissue and bone sarcomas. The 20 evaluable patients had received a median of three prior chemotherapeutic regimens, including an adriamycin combination, to which eight had shown response. PALA was administered at 2-week intervals. Sixteen patients received 6 g/m2 over 1 hour intravenously as their initial dose, while six patients received 5 g/m2. The major side effects were skin rash, stomatitis, diarrhea, nausea, and vomiting. Significant myelosuppression was not seen. Two patients had stabilization of disease for periods of 10 and 13 weeks. At the dose and schedule used in this trial, PALA was not effective against advanced adult sarcoma.
Insights
Pemetrexed disodium (PALA) showed limited efficacy in advanced adult sarcomas. This study found no significant benefit in patients with metastatic soft tissue and bone sarcomas.
Area of Science:
- Medical Oncology
- Pharmacological Research
- Sarcoma Treatment
Background:
- Advanced sarcomas, including soft tissue and bone types, present significant treatment challenges.
- Prior chemotherapy, such as adriamycin combinations, had limited success in the studied patient cohort.
- Evaluating novel therapeutic agents is crucial for improving outcomes in refractory sarcoma cases.
Purpose of the Study:
- To assess the efficacy and tolerability of Pemetrexed disodium (PALA) in patients with metastatic soft tissue and bone sarcomas.
- To determine the optimal dose and schedule for PALA in this patient population.
- To identify potential side effects and patient responses to PALA treatment.
Main Methods:
- A clinical trial involving 22 patients with metastatic soft tissue and bone sarcomas.
- Administration of PALA intravenously at 2-week intervals, with doses of 6 g/m2 or 5 g/m2.
- Evaluation of patient response based on disease stabilization and assessment of adverse events.
Main Results:
- Two patients experienced disease stabilization for 10 and 13 weeks.
- Major side effects included skin rash, stomatitis, diarrhea, nausea, and vomiting.
- No significant myelosuppression was observed in the trial participants.
Conclusions:
- Pemetrexed disodium (PALA) demonstrated limited efficacy in advanced adult sarcomas at the tested dose and schedule.
- Further research may be needed to explore alternative PALA regimens or combinations for sarcoma treatment.
- PALA was generally tolerated, with manageable gastrointestinal and dermatological side effects.